Description: EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.
Home Page: www.ekfdiagnostics.com
EKF Technical Analysis
Avon House
Cardiff,
CF64 2EZ
United Kingdom
Phone:
44 29 2071 0570
Officers
| Name | Title |
|---|---|
| Mr. David Michael Salter | CEO & Exec. Director |
| Mr. Marc Peter Davies | CFO & Director |
| Mr. Andrew Webb | Chief Exec. Officer of Ekf Molecular |
| Mr. Salim Hamir F.C.A. | Company Sec. |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 23 |
| Price-to-Book MRQ: | 2.3906 |
| Price-to-Sales TTM: | 2.5713 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 386 |